Foxx Development Holdings Inc. (NASDAQ:FOXX) Short Interest Update

Foxx Development Holdings Inc. (NASDAQ:FOXX) saw a significant decline in short interest in July. As of July 31st, there was short interest totaling 19,770 shares, a decline of 41.2% from the July 15th total of 33,622 shares. Based on an average trading volume of 8,351 shares, the short-interest ratio is presently 2.4 days. Approximately 0.4% of the shares of the stock are short sold.

Foxx Development Stock Performance

FOXX stock opened at $2.57 on Monday. Foxx Development has a 52 week low of $1.71 and a 52 week high of $7.90. The firm’s fifty day moving average is $3.00 and its 200 day moving average is $4.07. The firm has a market cap of $18.09 million, a P/E ratio of -0.37 and a beta of -0.35.

Foxx Development (NASDAQ:FOXX) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($5.19) earnings per share for the quarter. The business had revenue of $8.67 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Foxx Development presently has an average rating of “Sell”.

Institutional Investors Weigh In On Foxx Development

An institutional investor recently bought a new stake in Foxx Development stock. Citadel Advisors LLC bought a new stake in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned 0.18% of Foxx Development at the end of the most recent reporting period. 60.44% of the stock is currently owned by institutional investors.

About Foxx Development

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.